The Out-Sourcing/In-Sourcing/Out-Sourcing Model for Pharmacovigilance
Track
:
Track 14: Clinical Safety and Pharmacovigilance
Program Code:
343
Date:
Wednesday, June 27, 2012
Time:
10:00 AM to 11:30 AM
EST
CHAIR
:
Graeme Ladds, PharSafer Associates Ltd., United Kingdom
Having spent 11 years in Pharma Graeme left his position as Global Head of Drug Safety to start the CRO Company PharSafer in 2003 PharSafer specialises in Global Clinical & Post Marketing Pharmacovigilance & Medical Services looking after many varied Companies in all areas of Pharmacovigilance
PRESENTER
(S):
Graeme Ladds, PharSafer Associates Ltd., United Kingdom
Having spent 11 years in Pharma Graeme left his position as Global Head of Drug Safety to start the CRO Company PharSafer in 2003 PharSafer specialises in Global Clinical & Post Marketing Pharmacovigilance & Medical Services looking after many varied Companies in all areas of Pharmacovigilance
Dr. D,Cunha is presently the Director, Global Pharmacovigilance at Apotex Inc., presently responsible for Pharmacovigilance activities within the group. In addition, he is responsible to provide medical advice to the organization as appropriate. Prior to that he was Chief Medical Officer Ont.
Dr. Garrard is Chief Safety Officer for Drug Safety Alliance, Inc. She provides leadership in strategic planning, analysis, development, implementation and measurement of all aspects of drug safety and medical services including signal management and risk evaluation and mitigation strategy.
Description
The symposium will focus upon how to set up an outsourcing model that allows client oversight and future flexibility to in-source at a point in the future. Such a system can also be left open such that in times of need there is remaining flexibility once in-sourced to immediately out-source some aspects if the need arises. This will be a case study showing the scope, plan for transition, and what items to leave open for ensuring adaptability once in-sourced.
Learning Objectives: Identify the scope of Pharmacovigilance activities in a global environment Describe planning for transition, knowledge, capacity and transparency for staff regulators in Pharmacovigilance activities Explain the flexibility in systems and activities for future Pharmacovigilance support.